TGFB1 and keloid: Wang found that sorafenib was able to exert targeted inhibitory effects on the TGF-β/SMAD and MAPK/ERK signaling pathways, and may not only inhibit ECM proliferation, invasion, and production of KFs in vitro, but also exert inhibitory effects on KFs migration, angiogenesis, and collagen accumulation in keloid explants grown in vitro (111).